Co-targeting of delta-like ligand 4 (DLL4) and vascular endothelial growth factor a (VEGF) with programmed death 1 (PD1) blockade inhibits tumor growth and facilitates anti-tumor immune responses

نویسندگان

  • Minu Srivastava
  • Christopher Murriel
  • Rui Yun
  • Erin Mayes
  • Hyun-Bae Jie
  • Fumiko Axelrod
  • Ming-Hong Xie
  • Trevor Bentley
  • Belinda Cancilla
  • Raymond Tam
  • Gilbert O'Young
  • Ann Kapoun
  • John Lewicki
  • Tim Hoey
  • Austin Gurney
  • Park Angie Inkyung
چکیده

Co-targeting of delta-like ligand 4 (DLL4) and vascular endothelial growth factor a (VEGF) with programmed death 1 (PD1) blockade inhibits tumor growth and facilitates anti-tumor immune responses Minu Srivastava, Christopher Murriel, Rui Yun, Erin Mayes, Hyun-Bae Jie, Fumiko Axelrod, Ming-Hong Xie, Trevor Bentley, Belinda Cancilla, Raymond Tam, Gilbert O’Young, Ann Kapoun, John Lewicki, Tim Hoey, Austin Gurney, Park Angie Inkyung

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Up-regulation of the Notch ligand Delta-like 4 inhibits VEGF-induced endothelial cell function.

Delta-like 4 (Dll4), a membrane-bound ligand for Notch1 and Notch4, is selectively expressed in the developing endothelium and in some tumor endothelium, and it is induced by vascular endothelial growth factor (VEGF)-A and hypoxia. Gene targeting studies have shown that Dll4 is required for normal embryonic vascular remodeling, but the mechanisms underlying Dll4 regulatory functions are current...

متن کامل

HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY Up-regulation of the Notch ligand Delta-like 4 inhibits VEGF-induced endothelial cell function

Delta-like 4 (Dll4), a membrane-bound ligand for Notch1 and Notch4, is selectively expressed in the developing endothelium and in some tumor endothelium, and it is induced by vascular endothelial growth factor (VEGF)–A and hypoxia. Gene targeting studies have shown that Dll4 is required for normal embryonic vascular remodeling, but the mechanisms underlying Dll4 regulatory functions are current...

متن کامل

In vivo immunotherapy of lung cancer using cross-species reactive vascular endothelial growth factor nanobodies

Objective(s): Lung cancer is the main leading cause of cancer death worldwide. Angiogenesis is the main step in proliferation and spreading of tumor cells. Targeting vascular endothelial growth factor (VEGF) is an effective approach for inhibition of cancer angiogenesis. Nanobodies (NBs) are a novel class of antibodies derived from the camel. Unique characteristics of Nbs like their small size ...

متن کامل

Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo.

The vascular endothelial growth factor (VEGF) plays a key role in tumor angiogenesis. However, clinical trials targeting the VEGF pathway are often ineffective, suggesting that other factors/pathways are also important in tumor angiogenesis. We have previously shown that the Notch ligand Delta-like 4 (DLL4) is up-regulated in tumor vasculature. Here, we show that DLL4, when expressed in tumor c...

متن کامل

Dll4-Notch signaling as a therapeutic target in tumor angiogenesis

Tumor angiogenesis is an important target for cancer therapy, with most current therapies designed to block the VEGF signaling pathway. However, clinical resistance to anti-VEGF therapy highlights the need for targeting additional tumor angiogenesis signaling pathways. The endothelial Notch ligand Dll4 (delta-like 4) has recently emerged as a critical regulator of tumor angiogenesis and thus as...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره 3  شماره 

صفحات  -

تاریخ انتشار 2015